• Mashup Score: 2

    Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and dermatologist Dr. Saakshi Khattri discuss a new analysis of patient phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this conversation, they discuss disease activity differences between clinical trial populations and real-world patients, efficacy of an IL-23 inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23 inhibitor’s potential role in managing patients with PsA.

    Tweet Tweets with this article
    • Patient Phenotypes in PsA Clinical Trials of an IL-23 Inhibitor Dr. Alexis Ogdie and Dr. Saakshi Khattri discuss a new PsA phenotype analysis and potential clinical applications. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/kJeSteVoxE https://t.co/CBV09mzFUN

  • Mashup Score: 2

    Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and dermatologist Dr. Saakshi Khattri discuss a new analysis of patient phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this conversation, they discuss disease activity differences between clinical trial populations and real-world patients, efficacy of an IL-23 inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23 inhibitor’s potential role in managing patients with PsA.

    Tweet Tweets with this article
    • Patient Phenotypes in PsA Clinical Trials of an IL-23 Inhibitor Dr. Alexis Ogdie and Dr. Saakshi Khattri discuss a new PsA phenotype analysis and potential clinical applications. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/kJeSteVoxE https://t.co/CBV09mzFUN

  • Mashup Score: 2

    Catch up on the biggest breakthroughs, standout sessions, and expert insights from the third day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.

    Tweet Tweets with this article
    • Daily EULAR 2025 Recap Day 3 Catch up on the biggest breakthroughs, standout sessions, and expert insights from the third day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology. https://t.co/k0AV4tThWB https://t.co/Z9CVDLg5Tn

  • Mashup Score: 38

    A TriNetX EHR study shows that psoriatic arthritis, but not psoriasis, patients are at increased risk for interstitial lung disease (ILD).

    Tweet Tweets with this article
    • Psoriatic Arthritis at Risk for Interstitial Lung Disease A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD). https://t.co/2zuxF1PY3Q. https://t.co/r28dY3T8nO